Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma

Obstetrics and Gynecology

Volumn 80, Issue 6, 1992, Pages 949-953

  Soper, John T ^a,b   Johnson, Pamela ^a,b   Johnson, Valen ^a,b   Berchuck, Andrew ^a,b   Clarke Pearson, Daniel L ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; EARLY CANCER; FEMALE; HUMAN; LAPAROTOMY; OVARY CARCINOMA; PRIORITY JOURNAL; SECOND LOOK SURGERY;

ADULT; AGED; FEMALE; HUMAN; INTRAOPERATIVE COMPLICATIONS; LAPAROTOMY; MIDDLE AGE; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POSTOPERATIVE COMPLICATIONS; REOPERATION; RETROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T;

EID: 0026620771     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. DiSaia PJ, Creasman WT, eds. Clinical gynecologic oncology. 3rd ed. St. Louis: CV Mosby, 1989:292-416.
2. Young RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. JAMA 1983;250:3072-6.
3. Buchsbaum HJ, Brady MF, Delgado G, et al. Surgical staging of carcinoma of the ovaries. Surg Gynecol Obstet 1989;169:226-32.
4. McGowan L, Lesher LP, Norris HJ, Barnett M. Misstaging of ovarian cancer. Obstet Gynecol 1985;65:568-72.
5. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two randomized trials. N Engl J Med 1990;322:1021-7.
6. Clarke-Pearson DL, Bandy LC, Dudzinski M, Heaston D, Creasman W. Computed tomography in evaluation of patients with ovarian carcinoma in complete clinical remission. JAMA 1986;255: 627-30.
7. Piver MS, Barlow JJ, Lele SB. Incidence of subclinical metastasis in stage I and stage II ovarian carcinoma. Obstet Gynecol 1978; 52:100-4.
8. Iverson OE, Skaarland E. Ploidy assessment of benign and malignant ovarian tumors by flow cytometry. Cancer 1987;60: 82-7.
9. Kallioniemi OP, Punnonen R, Mattila J, Lehtinen M, Koivula T. Prognostic significance of DNA index, multiploidy, and S-phase fraction in ovarian cancer. Cancer 1988;61:334-9.
10. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-91.
11. Malkasian GD Jr, Knapp RC, Lavin PT, et al. Preoperative evaluation of serum CA-125 levels in postmenopausal patients with pelvic masses: Discrimination of benign from malignant disease. Am J Obstet Gynecol 1988;158:341-6.
12. Soper JT, Hunter VJ, Daly L, et al. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet Gynecol 1990;75:249-54.
13. Jacobs I, Bast RC Jr. The CA-125 tumor-associated antigen: A review of the literature. Hum Reprod 1989;4:1-12.
14. Granberg S, Wikland M, Jenssen I. Macroscopic characterization of tumors and the relation to the histological diagnosis: Criteria to be used for ultrasound evaluation. Gynecol Oncol 1989;35:139-44.
15. Weiner Z, Thaler I, Beck D, Rottem S, Deutsch M, Brandes JM. Differentiating malignant from benign ovarian tumors with trans-vaginal color flow imaging. Obstet Gynecol 1992;79:159-62.